Pistor M[au] - Search Results

Year	Number of Results
1904	1
1958	1
1976	1
2017	1
2018	2
2019	1
2020	2
2021	2
2022	5
2023	1

1

Different Fumaric Acid Esters Elicit Distinct Pharmacologic Responses.

Wipke BT, Hoepner R, Strassburger-Krogias K, Thomas AM, Gianni D, Szak S, Brennan MS, Pistor M, Gold R, Chan A, Scannevin RH. Wipke BT, et al. Among authors: pistor m. Neurol Neuroimmunol Neuroinflamm. 2021 Jan 19;8(2):e950. doi: 10.1212/NXI.0000000000000950. Print 2021 Mar. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 33468560 Free PMC article.

2

Application of the "risk of ambulatory disability" (RoAD) score in a "real-world" single-center multiple sclerosis cohort.

Pistor M, Hammer H, Salmen A, Hoepner R, Friedli C. Pistor M, et al. CNS Neurosci Ther. 2022 May;28(5):792-795. doi: 10.1111/cns.13806. Epub 2022 Jan 21. CNS Neurosci Ther. 2022. PMID: 35060326 Free PMC article.

3

Multiple Sclerosis immunotherapies and COVID-19 mortality: an analysis of the FDA Adverse Event Reporting System.

Pistor M, Hoepner R, Hoepner AGF, Lin Y, Jung S, Bassetti CL, Chan A, Salmen A. Pistor M, et al. Ther Adv Neurol Disord. 2022 Oct 10;15:17562864221129383. doi: 10.1177/17562864221129383. eCollection 2022. Ther Adv Neurol Disord. 2022. PMID: 36237201 Free PMC article.

4

Immunotherapies and COVID-19 mortality: a multidisciplinary open data analysis based on FDA's Adverse Event Reporting System.

Pistor M, Hoepner AGF, Lin Y, Jung S, Bassetti CL, Chan A, Salmen A, Hoepner R. Pistor M, et al. Ann Rheum Dis. 2021 Dec;80(12):1633-1635. doi: 10.1136/annrheumdis-2021-220679. Epub 2021 Jul 20. Ann Rheum Dis. 2021. PMID: 34285050 Free PMC article. No abstract available.

5

Ocrelizumab-related neutropenia: Effects of age, sex and bodyweight using the FDA Adverse Event Reporting System (FAERS).

Hammer H, Kamber N, Pistor M, Diem L, Friedli C, Chan A, Hoepner R, Salmen A. Hammer H, et al. Among authors: pistor m. Mult Scler Relat Disord. 2022 Sep;65:104015. doi: 10.1016/j.msard.2022.104015. Epub 2022 Jul 3. Mult Scler Relat Disord. 2022. PMID: 35810719

6

c-Jun N-Terminal Kinase as a Therapeutic Target in Experimental Autoimmune Encephalomyelitis.

Bagnoud M, Briner M, Remlinger J, Meli I, Schuetz S, Pistor M, Salmen A, Chan A, Hoepner R. Bagnoud M, et al. Among authors: pistor m. Cells. 2020 Sep 23;9(10):2154. doi: 10.3390/cells9102154. Cells. 2020. PMID: 32977663 Free PMC article.

7

Sex and gender differences in autoimmune demyelinating CNS disorders: Multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD) and myelin-oligodendrocyte-glycoprotein antibody associated disorder (MOGAD).

Diem L, Hammer H, Hoepner R, Pistor M, Remlinger J, Salmen A. Diem L, et al. Among authors: pistor m. Int Rev Neurobiol. 2022;164:129-178. doi: 10.1016/bs.irn.2022.06.011. Epub 2022 Aug 9. Int Rev Neurobiol. 2022. PMID: 36038203

8

Reliable brain morphometry from contrast-enhanced T1w-MRI in patients with multiple sclerosis.

Rebsamen M, McKinley R, Radojewski P, Pistor M, Friedli C, Hoepner R, Salmen A, Chan A, Reyes M, Wagner F, Wiest R, Rummel C. Rebsamen M, et al. Among authors: pistor m. Hum Brain Mapp. 2023 Feb 15;44(3):970-979. doi: 10.1002/hbm.26117. Epub 2022 Oct 17. Hum Brain Mapp. 2023. PMID: 36250711 Free PMC article.

9

Vitamin D supplementation differentially affects seasonal multiple sclerosis disease activity.

Miclea A, Miclea M, Pistor M, Hoepner A, Chan A, Hoepner R. Miclea A, et al. Among authors: pistor m. Brain Behav. 2017 Jul 11;7(8):e00761. doi: 10.1002/brb3.761. eCollection 2017 Aug. Brain Behav. 2017. PMID: 28828221 Free PMC article.

10

[What is mesotherapy?].

Pistor M. Pistor M. Chir Dent Fr. 1976 Jan 21;46(288):59-60. Chir Dent Fr. 1976. PMID: 1076080 French. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results